Register Now: Brain Organoid Virtual Symposium

Register Now

*Required

I would like to receive future communications from STEMCELL Technologies and OrganoVIR.

Register now for the virtual symposium hosted in collaboration with Organovir on October 9.

Brain Organoid Virtual Symposium

Presented by STEMCELL Technologies and OrganoVIR

Organoids have rapidly transformed researchers' ability to model human tissues in vitro. In neural research, organoids have revolutionized the study of brain development, health, and disease by enabling direct observations in human tissue—previously a significant challenge for both practical and ethical reasons.

Brain organoids present a unique opportunity for researchers to study viral pathogenesis in a human tissue model. During this virtual symposium, Drs. Vivi Heine (Amsterdam UMC), Veronica Krenn (IMBA), and Melvin Evers (uniQure) discuss how brain organoids are providing powerful model systems for understanding health and disease in a human-specific context.

Date and Time:

Friday, October 9, 2020
2:00 PM CEST (5:00 AM PDT, 8:00 AM EDT)

If you are unable to attend the live webinar, please register and a link will be sent to you with the recorded version.

Topics

Development of brain organoid models to study human neural development and disease
Modeling pathogenesis of infectious disease using brain organoids and their applications in virology research
Application of human-specific neural disease models in therapeutic development

Dr. Vivi Heine, PhD

Associate Professor, Amsterdam UMC

Vivi Heine is an Associate Professor of neuroscience and clinical genetics at Amsterdam UMC. Her research focuses on identifying and understanding the contributions of glial defects in neurodevelopmental disorders, and developing iPSC-based model systems to address basic and translational research questions.

Dr. Veronica Krenn, PhD

Postdoctoral Fellow, IMBA

Veronica is a cell biologist working as a postdoctoral researcher in the laboratory of Jürgen Knoblich at the Institute of Molecular Biotechnology (IMBA). There, she established several brain organoid infection models to study the impact of viruses on brain development. Using these models, she described unique aspects of viral pathogenesis and their contribution to brain damage.

Dr. Melvin Evers, PhD

Associate Director Research, Head of Emerging Targets and Technologies, uniQure

Melvin Evers is based at uniQure’s Amsterdam research hub, and is focused on the development of gene therapies for patients with serious unmet medical needs. He has been closely involved in the preclinical development of AMT-130, the gene therapy candidate for Huntington's disease, now in Phase I/IIa, as well as the early development of a gene therapy for spinocerebellar ataxia type 3 (SCA3).